You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Tumor Test to Predict Response to Enhertu® for People with Metastatic HER2 Low Breast Cancer

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Purpose: To study the ability of the CE-10-IVD test to predict treatment response to trastuzumab deruxtecan (T-DXd, Enhertu®).

Who is this for?: People with stage IV (metastatic) HER2 low (IHC 1+) breast cancer who are planning to receive or are receiving (within 1 month) trastuzumab deruxtecan (T-DXd, Enhertu®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor tissue from most recent biopsy, for CE-10-IVD test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The CE-10-IVD test measures the amount of HER2 positive (HER2+) breast cancer cells, which may relate to your response to trastuzumab deruxtecan (T-DXd, Enhertu®), an anti-HER2 targeted therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06551116' target='_blank'>ClinicalTrials.gov</a> </li></ul>
1

Tumor Test to Predict Response to Enhertu® for People with Metastatic HER2 Low Breast Cancer

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Icon

Nearest Location:
2517 miles
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, PA

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT06551116

Icon

Phase NA

HELP GUIDE
HELP GUIDE